{"id":"ado-trastuzumab-emtansine","safety":{"commonSideEffects":[{"rate":"~60%","effect":"Peripheral neuropathy"},{"rate":"~30%","effect":"Thrombocytopenia"},{"rate":"~20%","effect":"Elevated transaminases"},{"rate":"~40%","effect":"Fatigue"},{"rate":"~25%","effect":"Nausea"},{"rate":"~1-2%","effect":"Left ventricular dysfunction"}]},"_chembl":null,"_dailymed":{"setId":"23f3c1f4-0fc8-4804-a9e3-04cf25dd302e","title":"KADCYLA (ADO-TRASTUZUMAB EMTANSINE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [GENENTECH, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug combines trastuzumab (an anti-HER2 monoclonal antibody) with emtansine, a microtubule-disrupting agent, via a stable linker. The antibody portion recognizes and binds HER2 on cancer cell surfaces, allowing internalization and release of the cytotoxic payload inside the cell, which disrupts microtubule formation and triggers apoptosis. This targeted delivery mechanism reduces systemic toxicity compared to conventional chemotherapy.","oneSentence":"Ado trastuzumab emtansine is an antibody-drug conjugate that binds HER2-positive cancer cells and delivers a microtubule-disrupting toxin directly into them.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:21:00.486Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive metastatic breast cancer"},{"name":"HER2-positive early breast cancer (adjuvant treatment)"},{"name":"HER2-positive gastric or gastroesophageal junction adenocarcinoma"}]},"trialDetails":[{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT04158258","phase":"","title":"A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-02-21","conditions":"Breast Cancer","enrollment":2907},{"nctId":"NCT04266249","phase":"PHASE2","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-03-13","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":2175},{"nctId":"NCT06324357","phase":"PHASE1, PHASE2","title":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-06-03","conditions":"Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":768},{"nctId":"NCT05323955","phase":"PHASE2","title":"Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Carey Anders, M.D.","startDate":"2023-03-23","conditions":"Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer","enrollment":48},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT04589845","phase":"PHASE2","title":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-01-18","conditions":"Solid Tumors","enrollment":920},{"nctId":"NCT02675829","phase":"PHASE2","title":"Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-02","conditions":"Solid Tumor Cancers, Lung Cancer, Bladder Cancer","enrollment":131},{"nctId":"NCT04873362","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-04","conditions":"Breast Cancer","enrollment":1188},{"nctId":"NCT07421141","phase":"PHASE2","title":"De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Radiological Centre of the Ministry of Health of Russia","startDate":"2023-09-01","conditions":"Breast Cancer, HER2-positive Breast Cancer, Early Breast Cancer","enrollment":186},{"nctId":"NCT03523585","phase":"PHASE3","title":"DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2018-08-01","conditions":"Breast Cancer","enrollment":608},{"nctId":"NCT05593094","phase":"PHASE1, PHASE2","title":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-09-03","conditions":"Advanced Solid Tumors, HER2-positive Breast Cancer","enrollment":210},{"nctId":"NCT04893109","phase":"PHASE2","title":"ATEMPT 2.0: Adjuvant T-DM1 vs TH","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-06-16","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":500},{"nctId":"NCT05081609","phase":"PHASE1, PHASE2","title":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascendis Pharma Oncology Division A/S","startDate":"2022-01-11","conditions":"Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":320},{"nctId":"NCT04620187","phase":"PHASE2","title":"Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-12-24","conditions":"Salivary Gland Cancer, HER2 Gene Mutation","enrollment":55},{"nctId":"NCT01853748","phase":"PHASE2","title":"T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-05","conditions":"Breast Cancer","enrollment":512},{"nctId":"NCT06595563","phase":"PHASE2","title":"HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2026-02","conditions":"HER2-positive Metastatic Breast Cancer, HER2-positive Advanced Breast Cancer","enrollment":87},{"nctId":"NCT03587740","phase":"PHASE2","title":"ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-08-22","conditions":"Breast Cancer","enrollment":82},{"nctId":"NCT06348134","phase":"PHASE2","title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer","enrollment":74},{"nctId":"NCT02226276","phase":"NA","title":"Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2015-01-07","conditions":"Bone Metastases, HER2-positive Breast Cancer, Liver Metastases","enrollment":10},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT07389876","phase":"","title":"Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-09-01","conditions":"Gastric Cancer, Second-line Treatment","enrollment":250},{"nctId":"NCT01494662","phase":"PHASE2","title":"HKI-272 for HER2-Positive Breast Cancer and Brain Metastases","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2012-02","conditions":"Breast Cancer","enrollment":140},{"nctId":"NCT06830889","phase":"PHASE3","title":"A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-06-03","conditions":"HER2-positive Breast Cancer","enrollment":1450},{"nctId":"NCT05673928","phase":"PHASE2","title":"A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-05-16","conditions":"Metastatic Solid Tumor, Brain Metastases","enrollment":30},{"nctId":"NCT05408845","phase":"PHASE2","title":"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-03-03","conditions":"Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8","enrollment":146},{"nctId":"NCT07126561","phase":"PHASE2","title":"Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-11-01","conditions":"HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2","enrollment":43},{"nctId":"NCT04578106","phase":"PHASE2","title":"Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy","status":"TERMINATED","sponsor":"Fundacio Clinic Barcelona","startDate":"2020-09-23","conditions":"HER2-positive Breast Cancer, Stage I Breast Cancer","enrollment":5},{"nctId":"NCT00781612","phase":"PHASE2","title":"A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2008-10-16","conditions":"Neoplasm Metastasis","enrollment":720},{"nctId":"NCT03975647","phase":"PHASE3","title":"A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2019-10-02","conditions":"HER2-positive Breast Cancer","enrollment":466},{"nctId":"NCT07259226","phase":"PHASE2","title":"Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-11-14","conditions":"Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Urothelial Cancer","enrollment":400},{"nctId":"NCT06663787","phase":"","title":"Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment (HER2 CR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nagoya City University","startDate":"2024-04-01","conditions":"Breast Cancer, Metastatic, HER2 + Breast Cancer","enrollment":50},{"nctId":"NCT01975142","phase":"PHASE2","title":"Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2013-11-07","conditions":"Metastatic Breast Cancer, HER2 Negative Primary Tumor","enrollment":155},{"nctId":"NCT04439110","phase":"PHASE2","title":"Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-12","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":38},{"nctId":"NCT04733118","phase":"PHASE2","title":"Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2021-08-05","conditions":"Early Breast Cancer","enrollment":393},{"nctId":"NCT05889988","phase":"","title":"A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-06-12","conditions":"Breast Neoplasm","enrollment":36},{"nctId":"NCT04042701","phase":"PHASE1","title":"DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2020-02-10","conditions":"Breast Cancer, Non-small Cell Lung Carcinoma","enrollment":115},{"nctId":"NCT04457596","phase":"PHASE3","title":"T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-03-02","conditions":"Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8","enrollment":1056},{"nctId":"NCT03529110","phase":"PHASE3","title":"DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-08-09","conditions":"Breast Cancer","enrollment":524},{"nctId":"NCT04419181","phase":"PHASE2","title":"Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer","status":"WITHDRAWN","sponsor":"University of Rochester","startDate":"2025-08-11","conditions":"HER2-positive Breast Cancer","enrollment":""},{"nctId":"NCT05945927","phase":"","title":"A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2023-09-13","conditions":"Breast Cancer","enrollment":178},{"nctId":"NCT04486352","phase":"PHASE1, PHASE2","title":"A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer","status":"RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2021-10-20","conditions":"Endometrial Cancer","enrollment":148},{"nctId":"NCT07008976","phase":"PHASE3","title":"Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-07-07","conditions":"Metastatic Breast Cancer","enrollment":246},{"nctId":"NCT04740918","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2021-06-07","conditions":"Metastatic Breast Cancer","enrollment":96},{"nctId":"NCT04341181","phase":"PHASE2","title":"ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling","status":"RECRUITING","sponsor":"Ulrik Lassen","startDate":"2020-08-24","conditions":"Cancer, Tumors, Neoplasms","enrollment":300},{"nctId":"NCT04042051","phase":"PHASE1","title":"Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer","status":"TERMINATED","sponsor":"Cancer Trials Ireland","startDate":"2019-11-12","conditions":"HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer","enrollment":2},{"nctId":"NCT01772472","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-04-03","conditions":"Breast Cancer","enrollment":1486},{"nctId":"NCT05650879","phase":"PHASE1","title":"ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Enliven Therapeutics","startDate":"2023-03-20","conditions":"HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation","enrollment":198},{"nctId":"NCT03248492","phase":"PHASE2","title":"A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2017-08-25","conditions":"Breast Cancer","enrollment":253},{"nctId":"NCT06439693","phase":"PHASE2","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-08","conditions":"Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic","enrollment":72},{"nctId":"NCT07021911","phase":"","title":"Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Campus Bio-Medico","startDate":"2023-05-17","conditions":"Breast Cancer, Radiotherapy; Complications","enrollment":300},{"nctId":"NCT02314481","phase":"PHASE2","title":"Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2017-05-12","conditions":"Non-small Cell Lung Cancer","enrollment":50},{"nctId":"NCT06968585","phase":"PHASE3","title":"A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2023-07-18","conditions":"HER2-positive Breast Cancer","enrollment":365},{"nctId":"NCT04622319","phase":"PHASE3","title":"A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2020-12-04","conditions":"HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer","enrollment":1600},{"nctId":"NCT06126640","phase":"PHASE3","title":"A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-11-20","conditions":"HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy","enrollment":1600},{"nctId":"NCT05525858","phase":"","title":"KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II","status":"RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2022-09-28","conditions":"Solid Tumor, Advanced Solid Tumor, Metastatic Cancer","enrollment":1000},{"nctId":"NCT05288777","phase":"PHASE2, PHASE3","title":"Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2022-07-11","conditions":"Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II","enrollment":45},{"nctId":"NCT06928818","phase":"","title":"Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-02-26","conditions":"Cancer of Breast, Trastuzumab Emtansine, Trastuzumab Deruxtecan","enrollment":100},{"nctId":"NCT04680442","phase":"PHASE2","title":"Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2021-07-01","conditions":"Breast Cancer, Heart Failure","enrollment":130},{"nctId":"NCT04509596","phase":"PHASE1","title":"DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer","status":"COMPLETED","sponsor":"Dizal Pharmaceuticals","startDate":"2020-09-21","conditions":"Breast Cancer Metastatic","enrollment":23},{"nctId":"NCT01565200","phase":"PHASE2","title":"HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1","status":"COMPLETED","sponsor":"Jules Bordet Institute","startDate":"2012-05","conditions":"HER-2 Positive Breast Cancer","enrollment":90},{"nctId":"NCT06846437","phase":"PHASE3","title":"JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer","status":"RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2025-02-18","conditions":"Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants","enrollment":228},{"nctId":"NCT06877416","phase":"","title":"Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-01-01","conditions":"Antibody-drug Conjugates, HER2-low Breast Cancer, Breast Neoplasms","enrollment":700},{"nctId":"NCT02326974","phase":"PHASE2","title":"T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-01","conditions":"HER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer","enrollment":164},{"nctId":"NCT01745965","phase":"PHASE2","title":"A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2012-11","conditions":"Breast Cancer","enrollment":380},{"nctId":"NCT03523572","phase":"PHASE1","title":"Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2018-08-02","conditions":"Breast Cancer, Urothelial Carcinoma","enrollment":86},{"nctId":"NCT03032107","phase":"PHASE1","title":"A Study Of Pembrolizumab In Combination With Trastuzumab-DM1","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-02-17","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT04632992","phase":"PHASE2","title":"A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2021-01-13","conditions":"Advanced Unresectable or Metastatic Solid Malignancy","enrollment":252},{"nctId":"NCT06718335","phase":"NA","title":"Pyrotinib in HER2-positive Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Nie Jianyun","startDate":"2024-12-30","conditions":"HER2-positive Breast Cancer","enrollment":156},{"nctId":"NCT04675827","phase":"PHASE2","title":"De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2022-01-17","conditions":"HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer","enrollment":139},{"nctId":"NCT03726879","phase":"PHASE3","title":"A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-01-11","conditions":"Breast Cancer","enrollment":454},{"nctId":"NCT02390427","phase":"PHASE1","title":"Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer","status":"COMPLETED","sponsor":"Otto Metzger, MD","startDate":"2015-04-20","conditions":"Metastatic Breast Cancer, Recurrent Breast Cancer","enrollment":68},{"nctId":"NCT03530696","phase":"PHASE2","title":"T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2018-12-06","conditions":"HER2-positive Breast Cancer, Breast Cancer, Breast Cancer Stage","enrollment":55},{"nctId":"NCT06481956","phase":"PHASE2","title":"T-DM1 Combined With CDK4/6 Inhibitor Ribociclib","status":"ENROLLING_BY_INVITATION","sponsor":"Zheng Yabing","startDate":"2023-10-25","conditions":"HER2-positive Advanced Breast Cancer","enrollment":40},{"nctId":"NCT06313086","phase":"PHASE3","title":"DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-03-13","conditions":"HER2-positive Breast Cancer","enrollment":442},{"nctId":"NCT02448420","phase":"PHASE2","title":"Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2015-07","conditions":"Metastatic Breast Cancer","enrollment":73},{"nctId":"NCT06125834","phase":"PHASE2","title":"Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-06-01","conditions":"Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine","enrollment":36},{"nctId":"NCT06299852","phase":"NA","title":"Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer","status":"UNKNOWN","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2022-07-01","conditions":"HER2-positive Metastatic Breast Cancer, Oligometastatic Disease","enrollment":58},{"nctId":"NCT03709082","phase":"PHASE1, PHASE2","title":"Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer","status":"TERMINATED","sponsor":"University of Kansas Medical Center","startDate":"2018-10-15","conditions":"HER2-positive Breast Cancer, Breast Cancer Metastatic","enrollment":3},{"nctId":"NCT01120184","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-07-31","conditions":"Breast Cancer","enrollment":1095},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT03894410","phase":"","title":"Real World Study of Lapatinib Among Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"Fudan University","startDate":"2019-01-10","conditions":"Breast Cancer","enrollment":242},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT02564900","phase":"PHASE1","title":"Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2015-09-01","conditions":"Advanced Solid Tumors","enrollment":292},{"nctId":"NCT04197687","phase":"PHASE2","title":"TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery","status":"UNKNOWN","sponsor":"Academic and Community Cancer Research United","startDate":"2020-02-20","conditions":"Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7","enrollment":480},{"nctId":"NCT03190967","phase":"PHASE1, PHASE2","title":"T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-04-18","conditions":"Breast Cancer, Brain Metastasis, Brain Cancer","enrollment":12},{"nctId":"NCT04591431","phase":"PHASE2","title":"The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy","status":"UNKNOWN","sponsor":"Fondazione per la Medicina Personalizzata","startDate":"2020-10-07","conditions":"Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer","enrollment":400},{"nctId":"NCT05755048","phase":"PHASE3","title":"FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","startDate":"2023-03-28","conditions":"Breast Cancer","enrollment":314},{"nctId":"NCT03084939","phase":"PHASE3","title":"Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-04-24","conditions":"Breast Cancer","enrollment":351},{"nctId":"NCT04924699","phase":"PHASE2, PHASE3","title":"A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2021-06-30","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":350},{"nctId":"NCT05754502","phase":"","title":"Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy","status":"UNKNOWN","sponsor":"Consorzio Oncotech","startDate":"2021-07-27","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT05735392","phase":"NA","title":"Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial)","status":"COMPLETED","sponsor":"Consorzio Oncotech","startDate":"2018-11-07","conditions":"Metastatic Breast Cancer","enrollment":48},{"nctId":"NCT02236000","phase":"PHASE1, PHASE2","title":"A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2014-08","conditions":"Breast Cancer","enrollment":49},{"nctId":"NCT03829306","phase":"","title":"Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA)","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2018-06-12","conditions":"Advanced Breast Cancer","enrollment":32},{"nctId":"NCT03784599","phase":"PHASE2","title":"T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC","status":"TERMINATED","sponsor":"The Netherlands Cancer Institute","startDate":"2018-12-18","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":28},{"nctId":"NCT03364348","phase":"PHASE1","title":"4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"George W. Sledge Jr.","startDate":"2017-10-30","conditions":"HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer","enrollment":18},{"nctId":"NCT05560308","phase":"NA","title":"Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-09-30","conditions":"HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy","enrollment":50},{"nctId":"NCT04638725","phase":"","title":"Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Institut de cancérologie Strasbourg Europe","startDate":"2021-12-15","conditions":"HER2-positive Breast Cancer","enrollment":9000},{"nctId":"NCT02657343","phase":"PHASE1, PHASE2","title":"An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-03-09","conditions":"Breast Cancer","enrollment":25}],"_emaApprovals":[],"_faersSignals":[{"count":345,"reaction":"OFF LABEL USE"},{"count":295,"reaction":"DISEASE PROGRESSION"},{"count":289,"reaction":"DIARRHOEA"},{"count":215,"reaction":"NAUSEA"},{"count":189,"reaction":"FATIGUE"},{"count":153,"reaction":"THROMBOCYTOPENIA"},{"count":146,"reaction":"METASTASES TO CENTRAL NERVOUS SYSTEM"},{"count":142,"reaction":"NEUROPATHY PERIPHERAL"},{"count":136,"reaction":"VOMITING"},{"count":115,"reaction":"NEUTROPENIA"}],"_approvalHistory":[],"publicationCount":301,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Kadcyla"],"phase":"marketed","status":"active","brandName":"Ado Trastuzumab Emtansine","genericName":"Ado Trastuzumab Emtansine","companyName":"Medstar Health Research Institute","companyId":"medstar-health-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ado trastuzumab emtansine is an antibody-drug conjugate that binds HER2-positive cancer cells and delivers a microtubule-disrupting toxin directly into them. Used for HER2-positive metastatic breast cancer, HER2-positive early breast cancer (adjuvant treatment), HER2-positive gastric or gastroesophageal junction adenocarcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}